NKGen Biotech, Inc.
DelistedCIK 1845459fmd_00S93RYFN5C5SBRFF67KT639FFManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Dec 31, 2020 to Mar 31, 2025, 17 periods
Latest annual · FY2023
Millions- Total revenues
- 0
- Gross profit
- 0
- Operating income
- (27)
- Net income
- (44)
- Free cash flow
- (22)
Latest quarter · Q1 FY2025
Millions- Operating income
- (5)
- Net income
- 15
NKGen Biotech, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2024 | FY2023 | Change | Source |
|---|---|---|---|---|
| Operating income | -$27 million | -$29.7 million | 10-K 2025-10-08 · proof | |
| Net income | -$44.3 million | -$83 million | 10-K 2025-10-08 · proof | |
| Cash from operating activities | -$20.9 million | -$21.9 million | 10-K 2025-10-08 · proof | |
| Total assets | $16.2 million | $16.5 million | -1.5% | 10-K 2025-10-08 · proof |
| Total liabilities | $86.1 million | $75.2 million | +14.6% | 10-K 2025-10-08 · proof |
| Cash and cash equivalents | $106,000 | $26,000 | +307.7% | 10-K 2025-10-08 · proof |
- What was NKGen Biotech, Inc.'s operating income in fiscal 2024?
- NKGen Biotech, Inc. reported operating income of -$27 million for fiscal 2024 (the year ended Dec 31, 2024), against -$29.7 million the year before. Source: the 10-K filed with the SEC on Oct 8, 2025. SEC
- What was NKGen Biotech, Inc.'s net income in fiscal 2024?
- NKGen Biotech, Inc. reported net income of -$44.3 million for fiscal 2024 (the year ended Dec 31, 2024), against -$83 million the year before. Source: the 10-K filed with the SEC on Oct 8, 2025. SEC
- What was NKGen Biotech, Inc.'s cash from operating activities in fiscal 2024?
- NKGen Biotech, Inc. reported cash from operating activities of -$20.9 million for fiscal 2024 (the year ended Dec 31, 2024), against -$21.9 million the year before. Source: the 10-K filed with the SEC on Oct 8, 2025. SEC
- What are NKGen Biotech, Inc.'s total assets?
- As of Dec 31, 2024, NKGen Biotech, Inc. reported total assets of $16.2 million, against $16.5 million a year earlier (-1.5%). Source: the 10-K filed with the SEC on Oct 8, 2025. SEC
- What are NKGen Biotech, Inc.'s total liabilities?
- As of Dec 31, 2024, NKGen Biotech, Inc. reported total liabilities of $86.1 million, against $75.2 million a year earlier (+14.6%). Source: the 10-K filed with the SEC on Oct 8, 2025. SEC
- What are NKGen Biotech, Inc.'s cash and cash equivalents?
- As of Dec 31, 2024, NKGen Biotech, Inc. reported cash and cash equivalents of $106,000, against $26,000 a year earlier (+307.7%). Source: the 10-K filed with the SEC on Oct 8, 2025. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1845459&period_type=annual&limit=5"Information only, not investment advice.